Hero MotoCorp Q1 FY27 Results Analysis: Revenue Surges 35.7%, Margin Pressure Persists (HEROMOTOCO)
Hero MotoCorp Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 12,998.82 Cr (+35.70% YoY) and PAT growth of +29.21% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 06, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 12,998.82 Cr (+35.70% YoY) |
| PAT (Q1) | Rs. 1,454.48 Cr (+29.21% YoY) |
| EBITDA margin | 13.28% (-114 bps YoY) |
| EPS (Q1) | Rs. 72.69 (+29.20% YoY) |
| Market cap | Rs. 111,088.38 Cr |
| CMP | Rs. 5,550.50 |
Quarter Snapshot
Hero MotoCorp delivered strong revenue growth of 35.7% YoY and volume growth of 22.7%, outpacing the industry. However, EBITDA margin compressed to 13.28% due to a 523 bps surge in raw material costs, missing the 14-16% medium-term target. New growth drivers in EVs, scooters, and global business are promising, but margin recovery remains a key monitorable.
Key Investment Insights
Key Positives
- Revenue from operations grew 35.70% YoY to Rs.12,998.82 Cr.
- Volume grew 22.68% YoY to 16.77 lakh units, outpacing industry growth of 20.3%.
- Scooter dispatches more than doubled, global business grew 63% YoY, VIDA EV grew 151% YoY.
- Parts, Accessories, and Merchandise (PAM) revenue grew 30% YoY to Rs.1,689 Cr.
- Normalized consolidated PAT grew 25.88% YoY after adjusting for prior-year one-time gain.
- Standalone PAT grew 29.21% YoY to Rs.1,454.48 Cr.
Risk Factors
- EBITDA margin compressed 114 bps YoY to 13.28%, below the medium-term 14-16% target band.
- Raw material cost as a share of revenue surged 523 bps YoY to 70.95%, driven by commodity inflation.
- EBITDA margin declined 122 bps QoQ from 14.50% to 13.28%.
- Effective tax rate increased 133 bps YoY to 25.63%.
- Consolidated PAT declined 16.87% YoY on reported basis due to prior-year one-time gain of Rs.722 Cr.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.